FOXP3 and colonic neoplasm: One other direct comparison, companion to a meta-analysis, was published in 2010 by Nosho et al., who compared the prognostic power of CD45RO+, CD3+, CD8+, and FOXP3+ cells in neoplastic epithelial areas of 768 TMA from colon cancer patients, encompassing all stages [52].